Drugs that contain Bupivacaine
1. List of Exparel drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11278494 | PACIRA PHARMS INC | Manufacturing of bupivacaine multivesicular liposomes |
Jan, 2041
(17 years from now) | |
| US11179336 | PACIRA PHARMS INC | Manufacturing of bupivacaine multivesicular liposomes |
Jan, 2041
(17 years from now) | |
| US11426348 | PACIRA PHARMS INC | Compositions of bupivacaine multivesicular liposomes |
Jan, 2041
(17 years from now) | |
| US11452691 | PACIRA PHARMS INC | Compositions of bupivacaine multivesicular liposomes |
Jan, 2041
(17 years from now) | |
| US11357727 | PACIRA PHARMS INC | Manufacturing of bupivacaine multivesicular liposomes |
Jan, 2041
(17 years from now) | |
| US11311486 | PACIRA PHARMS INC | Manufacturing of bupivacaine multivesicular liposomes |
Jan, 2041
(17 years from now) | |
| US11304904 | PACIRA PHARMS INC | Manufacturing of bupivacaine multivesicular liposomes |
Jan, 2041
(17 years from now) | |
| US11033495 | PACIRA PHARMS INC | Manufacturing of bupivacaine multivesicular liposomes |
Jan, 2041
(17 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| New Patient Population (NPP) | Mar 22, 2024 |
Market Authorisation Date: 28 October, 2011
Treatment: Method of treating pain, for example, treating postsurgical pain via infiltration for local analgesia or via interscalene brachial plexus nerve block for regional analgesia; Method of treating pain, for example, via infiltration for local analgesia or via interscalene brachial plexus nerve block for regional analgesia; Method of treating pain, for example, via infiltration for local analgesia or via nerve block, for example, nterscalene brachial plexus for regional analgesia; Method of providing local or regional analgesia via infiltration for local analgesia or via interscalene brachial plexus nerve block or femoral nerve block for regional analgesia; Method of providing postsurgical pain management, for example, via infiltration for local analgesia or via interscalene brachial plexus nerve block for regional analgesia
Dosage: INJECTABLE, LIPOSOMAL;INJECTION
EXPAREL family patents
12
United States
1
United Kingdom
1
China
1
European Union
2. List of Posimir drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8846072 | DURECT | Controlled delivery system |
Sep, 2025
(2 years from now) | |
| US8153149 | DURECT | Controlled delivery system |
Sep, 2025
(2 years from now) | |
| US8153661 | DURECT | Controlled delivery system |
Sep, 2025
(2 years from now) | |
| US8753665 | DURECT | Controlled delivery system |
Sep, 2025
(2 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| New Product (NP) | Feb 1, 2024 |
Market Authorisation Date: 01 February, 2021
Treatment: Method for providing sustained local anesthesia for at least 24 hours
Dosage: SOLUTION, EXTENDED RELEASE;INFILTRATION
POSIMIR family patents
14
United States
4
European Union
3
Portugal
3
Spain
3
Cyprus
3
Slovenia
3
Poland
3
Denmark
2
Korea, Republic of
2
EA
2
Japan
1
Russia
1
Brazil
1
Croatia
1
New Zealand
1
Norway
1
Mexico
1
Austria
1
China
1
Hong Kong
1
South Africa
1
Lithuania
1
Canada
1
Hungary
1
Ukraine
1
Israel
1
Georgia
1
Australia
1
RS
3. List of Posimir drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11400019 | INNOCOLL | Sustained release drug delivery systems with reduced impurities and related methods |
Jan, 2041
(17 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| New Product (NP) | Feb 1, 2024 |
Market Authorisation Date: 01 February, 2021
Treatment: NA
Dosage: SOLUTION, EXTENDED RELEASE;INFILTRATION
POSIMIR family patents
4
United States
1
Korea, Republic of
1
Canada
1
Brazil
1
European Union
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic